SU616997A3 - Способ выделени компонентов гемагглютинина и нейраминидазы - Google Patents
Способ выделени компонентов гемагглютинина и нейраминидазыInfo
- Publication number
- SU616997A3 SU616997A3 SU752101722A SU2101722A SU616997A3 SU 616997 A3 SU616997 A3 SU 616997A3 SU 752101722 A SU752101722 A SU 752101722A SU 2101722 A SU2101722 A SU 2101722A SU 616997 A3 SU616997 A3 SU 616997A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- nitrogen
- detergent
- external
- sugar
- virus
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 102000005348 Neuraminidase Human genes 0.000 title 1
- 108010006232 Neuraminidase Proteins 0.000 title 1
- 239000000185 hemagglutinin Substances 0.000 title 1
- 239000003599 detergent Substances 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000007391 self-medication Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100478237 Caenorhabditis elegans ost-1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 235000004284 Vitis rupestris Nutrition 0.000 description 1
- 244000070471 Vitis rupestris Species 0.000 description 1
- KSPMJHKUXSQDSZ-UHFFFAOYSA-N [N].[N] Chemical class [N].[N] KSPMJHKUXSQDSZ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH44774A CH589453A5 (en:Method) | 1974-01-14 | 1974-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU616997A3 true SU616997A3 (ru) | 1978-07-25 |
Family
ID=4187233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU752101722A SU616997A3 (ru) | 1974-01-14 | 1975-01-14 | Способ выделени компонентов гемагглютинина и нейраминидазы |
Country Status (27)
| Country | Link |
|---|---|
| JP (2) | JPS58407B2 (en:Method) |
| AT (1) | AT345449B (en:Method) |
| AU (1) | AU500250B2 (en:Method) |
| BE (1) | BE824372A (en:Method) |
| CA (1) | CA1049406A (en:Method) |
| CH (1) | CH589453A5 (en:Method) |
| CS (1) | CS191254B2 (en:Method) |
| DD (1) | DD116239A5 (en:Method) |
| DE (1) | DE2500785B2 (en:Method) |
| DK (1) | DK140003B (en:Method) |
| ES (1) | ES433759A1 (en:Method) |
| FI (1) | FI54053C (en:Method) |
| FR (1) | FR2257305B1 (en:Method) |
| GB (1) | GB1498261A (en:Method) |
| HK (1) | HK56380A (en:Method) |
| HU (1) | HU173920B (en:Method) |
| IE (1) | IE40794B1 (en:Method) |
| IL (1) | IL46426A (en:Method) |
| MY (1) | MY8100204A (en:Method) |
| NL (1) | NL166622C (en:Method) |
| NO (1) | NO143128C (en:Method) |
| PH (1) | PH14458A (en:Method) |
| PL (1) | PL93689B1 (en:Method) |
| SE (1) | SE427238B (en:Method) |
| SU (1) | SU616997A3 (en:Method) |
| YU (1) | YU41289B (en:Method) |
| ZA (1) | ZA75259B (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2829089A1 (de) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | Subunit-vakzine |
| JPH0688911B2 (ja) * | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | インフルエンザワクチン及びその製造方法 |
| TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| EP0919243A1 (en) | 1997-11-25 | 1999-06-02 | Duphar International Research B.V | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
| DE19938767C2 (de) * | 1999-08-16 | 2002-10-24 | Tad Pharma Gmbh | Spaltimpfstoffe |
| CA2627971A1 (en) * | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| EP2192917B1 (en) * | 2007-08-28 | 2014-01-29 | Baxter International Inc. | Method for producing viral vaccines |
| JP6373376B2 (ja) | 2013-11-15 | 2018-08-15 | ノバルティス アーゲー | 残留細胞培養不純物の除去 |
-
1974
- 1974-01-14 CH CH44774A patent/CH589453A5/xx not_active IP Right Cessation
-
1975
- 1975-01-06 FI FI750014A patent/FI54053C/fi not_active IP Right Cessation
- 1975-01-06 NO NO750031A patent/NO143128C/no unknown
- 1975-01-06 DK DK1475AA patent/DK140003B/da not_active IP Right Cessation
- 1975-01-07 SE SE7500130A patent/SE427238B/xx not_active IP Right Cessation
- 1975-01-10 NL NL7500301.A patent/NL166622C/xx not_active IP Right Cessation
- 1975-01-10 DE DE2500785A patent/DE2500785B2/de active Granted
- 1975-01-13 PL PL1975177303A patent/PL93689B1/pl unknown
- 1975-01-13 AT AT21475A patent/AT345449B/de not_active IP Right Cessation
- 1975-01-13 IE IE59/75A patent/IE40794B1/xx unknown
- 1975-01-13 CA CA217,790A patent/CA1049406A/en not_active Expired
- 1975-01-13 ES ES433759A patent/ES433759A1/es not_active Expired
- 1975-01-13 HU HU75SA2736A patent/HU173920B/hu not_active IP Right Cessation
- 1975-01-13 YU YU58/75A patent/YU41289B/xx unknown
- 1975-01-13 IL IL46426A patent/IL46426A/xx unknown
- 1975-01-13 GB GB1290/75A patent/GB1498261A/en not_active Expired
- 1975-01-13 DD DD183614A patent/DD116239A5/xx unknown
- 1975-01-13 PH PH16702A patent/PH14458A/en unknown
- 1975-01-14 FR FR7501007A patent/FR2257305B1/fr not_active Expired
- 1975-01-14 CS CS75255A patent/CS191254B2/cs unknown
- 1975-01-14 BE BE152368A patent/BE824372A/xx not_active IP Right Cessation
- 1975-01-14 AU AU77305/75A patent/AU500250B2/en not_active Expired
- 1975-01-14 SU SU752101722A patent/SU616997A3/ru active
- 1975-01-14 ZA ZA00750259A patent/ZA75259B/xx unknown
- 1975-01-14 JP JP50006975A patent/JPS58407B2/ja not_active Expired
-
1980
- 1980-10-09 HK HK563/80A patent/HK56380A/xx unknown
-
1981
- 1981-01-29 JP JP56012831A patent/JPS6035326B2/ja not_active Expired
- 1981-12-30 MY MY204/81A patent/MY8100204A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU616997A3 (ru) | Способ выделени компонентов гемагглютинина и нейраминидазы | |
| EP0484787A2 (de) | HCV-spezifische Peptide, Mittel dazu und ihre Verwendung | |
| CA1058075A (en) | Process of improving the compatibility of gamma globulins | |
| US20070049732A1 (en) | Ultra-high yield intravenous immune globulin preparation | |
| US4199450A (en) | Process of separating from an aqueous medium a protein or a morphologically organized unit by liquid exclusion chromatography | |
| EP0037931A3 (de) | Verfahren zur Herstellung eines immunogenen Membranprotein-aggregats von Influenza-, Parainfluenza- und Rhabdo-Viren | |
| US4206014A (en) | Process for removing detergents from virus-antigen suspensions | |
| Shedlovsky et al. | THE LS-ANTIGEN OF VACCINIA: II. Isolation of a Single Substance Containing Both L-and S-Activity | |
| EP1356829A2 (en) | Preparation of virally inactivated intravenously injectable immune serum globulin | |
| US4476109A (en) | Method of preparing gamma globulin suitable for intravenous administration | |
| US2793203A (en) | Process of preparing stable, highly purified gamma globulin preparations | |
| JPS6072818A (ja) | ヒト血漿の低温殺菌法 | |
| Bitsch | An investigation into the basic virus-antibody neutralization reaction, with special regard to the reaction in the constant-virus/varying-serum neutralization test | |
| US3203865A (en) | Hog serum antibody concentrate | |
| EP0066932A1 (en) | Virus vaccines and process for preparing the same | |
| US2369111A (en) | Blood clotting accelerator | |
| US4948877A (en) | Preparation of retrovirus-free immunoglobulins | |
| SU1409121A3 (ru) | Способ получени поверхностного антигена гепатита В из плазмы крови человека | |
| SU1102605A1 (ru) | Способ получени диагностического иммуноглобулина к вирусу Западного Нила | |
| US3630840A (en) | Process for purifying solutions of the foot-and-mouth disease virus | |
| SU1140788A1 (ru) | Способ получени эритроцитарного диагностикума | |
| Stedman et al. | Purification of Newcastle disease virus antibody from the egg yolk of the hen | |
| HEIDELERGER | Complement: immunity intensifier, diagnostic drudge, chemical curiosity | |
| Gill | Serological properties of oat necrotic mottle virus | |
| Gajdusek | Suspended Cell Tissue Cultures for Study of Virus Growth Kinetics. |